Do you have Myotonic Dystrophy Type 1 (DM1) or Type 2 (DM2)?

Learn more about a clinical research study evaluating if mexiletine prolonged release (PR) is safe and effective in alleviating muscle stiffness and improving quality of life.

The HERCULES clinical study is the first of its kind evaluating if an investigational medication, called mexiletine prolonged release (PR), is safe and effective in alleviating muscle stiffness and improving daily activity and quality of life in people diagnosed with myotonic dystrophy type 1 or type 2 (DM1 or DM2). The study will include a total of 96 patients across different countries in Europe and the United Kingdom.

You may qualify if you are:

- At least 16 years of age*
- Diagnosed with DM1 or DM2

**Participants under the age of 18 will need approval from a responsible adult to participate.*

Qualified patients will receive study-related examinations and medication at no cost.

Study participation in HERCULES will last for 6 months. Participants will have an equal chance of receiving either mexiletine PR or placebo (a drug with no active ingredient). Participants will then be eligible to join a follow-up study, called ATLAS, for 18 months where all participants will receive treatment with mexiletine PR. ATLAS will evaluate long-term safety and effectiveness of mexiletine PR. Your health and safety will be closely monitored throughout both studies.

Mexiletine (NaMuscla®) has been approved as an antimyotonic treatment in adults with non-dystrophic myotonic (NDM) disorders. It is a safe and efficacious treatment. HERCULES and ATLAS will provide information on the safety and effectiveness of mexiletine's PR formulation in people with DM1 and DM2.

Scan this code using a QR reader on your smartphone to visit www.MyotonicDystrophyStudy.com for more information and to see if you qualify.

HERCULES